RETRACTED ARTICLE: Hybrid nanoparticulate system of Fluvastatin loaded phospholipid, alpha lipoic acid and melittin for the management of colon cancer
Abstract As a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, Fluvastatin (FLV) is used for reducing low-density lipoprotein (LDL) cholesterol as well as to prevent cardiovascular problems. FLV showed cell line cytotoxicity and antitumor effect. Melittin (MEL) exhibits antineoplastic...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-11-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-24151-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846165223380090880 |
|---|---|
| author | Mohamed A. Alfaleh Omar Fahmy Mohammed W. Al-Rabia Mohammed A. S. Abourehab Osama A. A. Ahmed Usama A. Fahmy Helal H. Alsulimani Shaimaa M. Badr-Eldin Hibah M. Aldawsari Bander M. Aldhabi Awaad S. Alharbi Nabil A. Alhakamy |
| author_facet | Mohamed A. Alfaleh Omar Fahmy Mohammed W. Al-Rabia Mohammed A. S. Abourehab Osama A. A. Ahmed Usama A. Fahmy Helal H. Alsulimani Shaimaa M. Badr-Eldin Hibah M. Aldawsari Bander M. Aldhabi Awaad S. Alharbi Nabil A. Alhakamy |
| author_sort | Mohamed A. Alfaleh |
| collection | DOAJ |
| description | Abstract As a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, Fluvastatin (FLV) is used for reducing low-density lipoprotein (LDL) cholesterol as well as to prevent cardiovascular problems. FLV showed cell line cytotoxicity and antitumor effect. Melittin (MEL) exhibits antineoplastic activity and is known to be promising as a therapeutic option for cancer patients. The aim of this work was to investigate the combination of FLV with MEL loaded hybrid formula of phospholipid (PL) with alpha lipoic acid (ALA) nanoparticles to maximize anticancer tendencies. This study examines the optimization of the prepared formulation in order to minimize nanoparticles size and maximize zeta potential to potentiate cytotoxic potentialities in colon cancer cells (Caco2), cell viability, cell cycle analysis and annexin V were tested. In addition to biological markers as P53, Bax, bcl2 and Caspase 3 evaluation The combination involving FLV PL ALA MEL showed enhanced cytotoxic potentiality (IC50 = 9.242 ± 0.35 µg/mL), about twofold lower, compared to the raw FLV (IC50 = 21.74 ± 0.82 µg/mL). According to studies analyzing cell cycle, optimized FLV PL ALA MEL was found to inhibit Caco2 colon cancer cells more significantly than other therapeutic treatments, wherein a higher number of cells were found to accumulate over G2/M and pre-G1 phases, whereas G0/G1/S phases witnessed the accumulation of a lower number of cells. The optimized formulation may pave the way for a novel and more efficacious treatment for colon cancer. |
| format | Article |
| id | doaj-art-e588d3a2f1714a00a03b55b2e00bfbd0 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2022-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-e588d3a2f1714a00a03b55b2e00bfbd02024-11-17T12:30:21ZengNature PortfolioScientific Reports2045-23222022-11-0112111610.1038/s41598-022-24151-3RETRACTED ARTICLE: Hybrid nanoparticulate system of Fluvastatin loaded phospholipid, alpha lipoic acid and melittin for the management of colon cancerMohamed A. Alfaleh0Omar Fahmy1Mohammed W. Al-Rabia2Mohammed A. S. Abourehab3Osama A. A. Ahmed4Usama A. Fahmy5Helal H. Alsulimani6Shaimaa M. Badr-Eldin7Hibah M. Aldawsari8Bander M. Aldhabi9Awaad S. Alharbi10Nabil A. Alhakamy11Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz UniversityDepartment of Urology, Universiti Putra MalaysiaDepartment of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz UniversityDepartment of Pharmaceutics, and Industrial Pharmacy, Faculty, of Pharmacy, Minia UniversityDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz UniversityDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz UniversityDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz UniversityDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz UniversityDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz UniversityDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz UniversityDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz UniversityDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz UniversityAbstract As a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, Fluvastatin (FLV) is used for reducing low-density lipoprotein (LDL) cholesterol as well as to prevent cardiovascular problems. FLV showed cell line cytotoxicity and antitumor effect. Melittin (MEL) exhibits antineoplastic activity and is known to be promising as a therapeutic option for cancer patients. The aim of this work was to investigate the combination of FLV with MEL loaded hybrid formula of phospholipid (PL) with alpha lipoic acid (ALA) nanoparticles to maximize anticancer tendencies. This study examines the optimization of the prepared formulation in order to minimize nanoparticles size and maximize zeta potential to potentiate cytotoxic potentialities in colon cancer cells (Caco2), cell viability, cell cycle analysis and annexin V were tested. In addition to biological markers as P53, Bax, bcl2 and Caspase 3 evaluation The combination involving FLV PL ALA MEL showed enhanced cytotoxic potentiality (IC50 = 9.242 ± 0.35 µg/mL), about twofold lower, compared to the raw FLV (IC50 = 21.74 ± 0.82 µg/mL). According to studies analyzing cell cycle, optimized FLV PL ALA MEL was found to inhibit Caco2 colon cancer cells more significantly than other therapeutic treatments, wherein a higher number of cells were found to accumulate over G2/M and pre-G1 phases, whereas G0/G1/S phases witnessed the accumulation of a lower number of cells. The optimized formulation may pave the way for a novel and more efficacious treatment for colon cancer.https://doi.org/10.1038/s41598-022-24151-3 |
| spellingShingle | Mohamed A. Alfaleh Omar Fahmy Mohammed W. Al-Rabia Mohammed A. S. Abourehab Osama A. A. Ahmed Usama A. Fahmy Helal H. Alsulimani Shaimaa M. Badr-Eldin Hibah M. Aldawsari Bander M. Aldhabi Awaad S. Alharbi Nabil A. Alhakamy RETRACTED ARTICLE: Hybrid nanoparticulate system of Fluvastatin loaded phospholipid, alpha lipoic acid and melittin for the management of colon cancer Scientific Reports |
| title | RETRACTED ARTICLE: Hybrid nanoparticulate system of Fluvastatin loaded phospholipid, alpha lipoic acid and melittin for the management of colon cancer |
| title_full | RETRACTED ARTICLE: Hybrid nanoparticulate system of Fluvastatin loaded phospholipid, alpha lipoic acid and melittin for the management of colon cancer |
| title_fullStr | RETRACTED ARTICLE: Hybrid nanoparticulate system of Fluvastatin loaded phospholipid, alpha lipoic acid and melittin for the management of colon cancer |
| title_full_unstemmed | RETRACTED ARTICLE: Hybrid nanoparticulate system of Fluvastatin loaded phospholipid, alpha lipoic acid and melittin for the management of colon cancer |
| title_short | RETRACTED ARTICLE: Hybrid nanoparticulate system of Fluvastatin loaded phospholipid, alpha lipoic acid and melittin for the management of colon cancer |
| title_sort | retracted article hybrid nanoparticulate system of fluvastatin loaded phospholipid alpha lipoic acid and melittin for the management of colon cancer |
| url | https://doi.org/10.1038/s41598-022-24151-3 |
| work_keys_str_mv | AT mohamedaalfaleh retractedarticlehybridnanoparticulatesystemoffluvastatinloadedphospholipidalphalipoicacidandmelittinforthemanagementofcoloncancer AT omarfahmy retractedarticlehybridnanoparticulatesystemoffluvastatinloadedphospholipidalphalipoicacidandmelittinforthemanagementofcoloncancer AT mohammedwalrabia retractedarticlehybridnanoparticulatesystemoffluvastatinloadedphospholipidalphalipoicacidandmelittinforthemanagementofcoloncancer AT mohammedasabourehab retractedarticlehybridnanoparticulatesystemoffluvastatinloadedphospholipidalphalipoicacidandmelittinforthemanagementofcoloncancer AT osamaaaahmed retractedarticlehybridnanoparticulatesystemoffluvastatinloadedphospholipidalphalipoicacidandmelittinforthemanagementofcoloncancer AT usamaafahmy retractedarticlehybridnanoparticulatesystemoffluvastatinloadedphospholipidalphalipoicacidandmelittinforthemanagementofcoloncancer AT helalhalsulimani retractedarticlehybridnanoparticulatesystemoffluvastatinloadedphospholipidalphalipoicacidandmelittinforthemanagementofcoloncancer AT shaimaambadreldin retractedarticlehybridnanoparticulatesystemoffluvastatinloadedphospholipidalphalipoicacidandmelittinforthemanagementofcoloncancer AT hibahmaldawsari retractedarticlehybridnanoparticulatesystemoffluvastatinloadedphospholipidalphalipoicacidandmelittinforthemanagementofcoloncancer AT bandermaldhabi retractedarticlehybridnanoparticulatesystemoffluvastatinloadedphospholipidalphalipoicacidandmelittinforthemanagementofcoloncancer AT awaadsalharbi retractedarticlehybridnanoparticulatesystemoffluvastatinloadedphospholipidalphalipoicacidandmelittinforthemanagementofcoloncancer AT nabilaalhakamy retractedarticlehybridnanoparticulatesystemoffluvastatinloadedphospholipidalphalipoicacidandmelittinforthemanagementofcoloncancer |